Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA
TipRanks (Tue, 16-Jun 9:49 AM ET)
Outlook gains as wet AMD therapy reconsidered for FDA review
Seeking Alpha News (Tue, 16-Jun 9:23 AM ET)
Globe Newswire (Tue, 16-Jun 8:02 AM ET)
Globe Newswire (Mon, 1-Jun 8:46 AM ET)
Globe Newswire (Thu, 28-May 4:00 PM ET)
FDA Appeal Win Clears Path for Outlook Therapeutics' LYTENAVA—Resubmission Expected Next Month
Market Chameleon (Wed, 27-May 6:33 AM ET)
FDA Appeal Win Clears Path for Outlook Therapeutics' ONS-5010/LYTENAVA to Resubmit for Approval
Market Chameleon (Tue, 26-May 5:52 AM ET)
Globe Newswire (Tue, 26-May 7:00 AM ET)
Globe Newswire (Fri, 15-May 4:05 PM ET)
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Globe Newswire (Thu, 23-Apr 4:05 PM ET)
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.
As of June 18, 2026, OTLK stock price declined to $1.58 with 18,593,083 million shares trading.
OTLK has a beta of 3.30, meaning it tends to be more sensitive to market movements. OTLK has a correlation of 0.04 to the broad based SPY ETF.
OTLK has a market cap of $234.77 million. This is considered a Small Cap stock.
Last quarter Outlook Therapeutics reported $128,000 in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.04.
In the last 3 years, OTLK traded as high as $37.00 and as low as $.16.
The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, VXF, IWC.
OTLK has underperformed the market in the last year with a return of -6.5%, while SPY returned +26.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OTLK shares. However, OTLK has outperformed the market in the last 3 month and 2 week periods, returning +299.3% and +95.1%, while SPY returned +11.6% and -1.0%, respectively. This indicates OTLK has been having a stronger performance recently.
OTLK support price is $1.41 and resistance is $1.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK shares will trade within this expected range on the day.
